van Doorninck J H, French P J, Verbeek E, Peters R H, Morreau H, Bijman J, Scholte B J
MGC-Department of Cell Biology and Genetics, Erasmus University, Rotterdam, The Netherlands.
EMBO J. 1995 Sep 15;14(18):4403-11. doi: 10.1002/j.1460-2075.1995.tb00119.x.
Most cystic fibrosis (CF) patients produce a mutant form (delta F508) of the cystic fibrosis transmembrane conductance regulator (CFTR), which is not properly processed in normal cells but is active as a chloride channel in several experimental systems. We used a double homologous recombination ('Hit and Run') procedure to generate a mouse model for the delta F508 mutation. Targeted embryonic stem (ES) cells (Hit clones) were found; of these either 80 or 20% of the clones had lost the delta F508 mutation, depending on the distance between the linearization site in the targeting construct and the delta F508 mutation. Correctly targeted clones underwent a second selection step resulting in ES cell clones (Run clones) heterozygous for the delta F508 mutation with an efficiency of 2-7%. Chimeric mice were generated and offspring homozygous for the delta F508 mutation showed electrophysiological abnormalities in nasal epithelium, gallbladder and in the intestine, and histological abnormalities in the intestine, typical of CF. Our data suggest that the delta F508 mice have residual delta F508 CFTR activity which would explain the mild pathology of the delta F508 mice. The delta F508 mouse may provide a useful model for the study of the processing defect of delta F508 CFTR and for the development of novel therapeutic approaches based on circumvention of the processing block.
大多数囊性纤维化(CF)患者会产生囊性纤维化跨膜传导调节因子(CFTR)的一种突变形式(ΔF508),该突变形式在正常细胞中无法正常加工,但在多个实验系统中作为氯离子通道具有活性。我们使用了双同源重组(“打了就跑”)程序来生成ΔF508突变的小鼠模型。找到了靶向胚胎干细胞(ES细胞)(打靶克隆);其中80%或20%的克隆根据打靶构建体中的线性化位点与ΔF508突变之间的距离而失去了ΔF508突变。正确靶向的克隆经过第二步筛选,得到了对ΔF508突变杂合的ES细胞克隆(跑克隆),效率为2%-7%。生成了嵌合小鼠,ΔF508突变纯合的后代在鼻上皮、胆囊和肠道中表现出电生理异常,在肠道中表现出组织学异常,这是CF的典型特征。我们的数据表明,ΔF508小鼠具有残余的ΔF508 CFTR活性,这可以解释ΔF508小鼠的轻度病理表现。ΔF508小鼠可能为研究ΔF508 CFTR的加工缺陷以及基于绕过加工障碍开发新的治疗方法提供有用的模型。